Since NSCLC is typified by several gene point mutations and about 70% of NSCLC patients experience somatic mutations in the exons of the epidermal growth factor receptor (EGFR) gene [13,14], small-molecule EGFR tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib and gefitinib have been included as the second-line treatment for NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.